Baxter Secures FDA Approval of Clinolipid (Lipid Injectable Emulsion) Neonatal and Pediatric Indication
May 14, 2024
May 14, 2024
DEERFIELD, Illinois, May 14 -- Baxter International, a health care company that focuses on products to treat hemophilia, kidney disease, immune disorders and other chronic and acute medical conditions, issued the following news release on May 13, 2024:
Baxter International Inc. (NYSE:BAX), a global leader in nutrition therapy, today announced U.S. FDA approval of an expanded indication for Clinolipid (Lipid Injectable Emulsion) to be used in pediatric patients, including preterm and . . .
Baxter International Inc. (NYSE:BAX), a global leader in nutrition therapy, today announced U.S. FDA approval of an expanded indication for Clinolipid (Lipid Injectable Emulsion) to be used in pediatric patients, including preterm and . . .